Targovax ASA Entered into a Clinical Collaboration and Supply Agreement with Agenus TG Mutant KRAS Cancer Adjuvanted with QS-21 STIMULON
Shots:
- The companies collaborated to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´ QS-21 STIMULON adjuvant technology
- Agenus will be responsible to supply QS-21 STIMULON and providing scientific support for up to three initial TG01 clinical trials in different cancer indications. Additionally, QS-21 STIMULON demonstrated powerful Ab and cell-mediated immune responses along with a favorable safety profile
- The collaboration may be extended into a development and commercialization agreement for KRAS vaccination if the combination proves effective in exploratory clinical studies where Agenus will be eligible to receive royalties on future TG vaccine sales
Ref: Targovax | Image: Targovax
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
